我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

替米沙坦联合辛伐他汀治疗慢性充血性心力衰竭的疗效

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2010年第1期
页码:
78-80，83
栏目:
临床研究
出版日期:
2010-01-04

文章信息/Info

Title:
Efficacy of telmisartan combined with simvastatin in patients with congestive heart failure
作者:
黄善庆; 陈丽媛; 仇昌智
钦州市第二人民医院，广西 钦州 535000
Author(s):
HUANG Shan-qing;  CHEN Li-yuan;  QIU Chang-zhi
Second People's Hospital of Qingzhou, Qingzhou 535000, Guangxi, China
关键词:
心力衰竭; 充血性; 替米沙坦; 辛伐他汀; 心功能
Keywords:
congestive heart failure;  telmisartan;  simvastatin;  heart function
分类号:
R541.61
DOI:
-
文献标识码:
A
摘要:
目的: 观察替米沙坦联合辛伐他汀治疗慢性充血性心力衰竭（CHF）的疗效。方法: 将132例CHF患者随机分为替米沙坦联合辛伐他汀治疗组（联合治疗组，44例）、辛伐他汀组（44例）和常规对照组（44例）3组，随访180 d，观察治疗前后NYHA心功能分级，同时以超声动图检测左室舒张末期内径（LVEDD）、左室收缩末期内径（LVESD）、左室射血分数（LVEF）及E/A来评估治疗效果。结果: 联合治疗组疗效优于辛伐他汀组和常规对照组（P<0.05）。辛伐他汀组各指标均优于常规对照组，差异有统计学意义（P<0.05）。LVEF（％）、E/A联合治疗组均优于辛伐他汀组，差异有统计学意义（P<0.05）。结论: 替米沙坦联合辛伐他汀治疗CHF比单用辛伐他汀的临床疗效更好。
Abstract:
AIM: To investigate the clinical therapeutic efficacy of telmisartan combined with simvastatin in patients with congestive heart failure (CHF). METHODS: A total of 132 patients with CHF were randomly divided into group A (routine treatment group), group B (simvastatin treatment group) and group C (telmisartan+simvastatin treatment group). The clinical therapeutic efficacy as well as LVEDD, LVESD, LVEF and E/A were analyzed before and 180 days after treatment. RESULTS: Significant differences were found in the clinical therapeutic efficacy and left ventricular functions among the three groups before treatment and 180 days after treatment (P<0.05). In group B and group C, left ventricular functions improved more significantly than in group A (P<0.05). In group C, left ventricular function obviously increased, compared with group B (P<0.05). CONCLUSION: Combined administration of telmisartan and simvastatinv exerts better effects on patients with CHF than a single administration of simvastatin (P<0.05).

参考文献/References

［1］ 刘娟,张程立. 他汀类药物相关肌病临床研究进展［J］. 内科, 2007, 2(1):107-109.

［2］ Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult:a report of the American College of Cardiology/Americah Heart Association Task Force on Practice Guidelines(Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)［J］. J Am Coll Cardiol, 2005, 46(6):e1-e82.

［3］ Pourati I, Kimmelstiel C, Rand W, et al. Statin use is associated with enhanced collateralization lr severely diseased coronary arteries［J］. Am Heart J, 2003, 146(5):876-881.

［4］ Pliquett RU, Cormish KG, Peuler JD, et al. Simvastatin mormalizes autonomic meural control im experimental heart failure［J］. Circulation, 2003, 107(19):2493-2498.

［5］ Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with pravastatin in Ischaemic Disease（LIPID）Studay Group［J］. N Engl J Med, 1998, 339（19）:1349-1357.

［6］ 尹芝兰，赵水平，周宏年. 充血性心力衰竭患者血清细胞因子的变化及辛伐他汀的干预作用［J］. 中国现代医学杂志, 2003, 13(6):47-51.

［7］ Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotensin Ⅱ type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells［J］. Arterioscler Thromb Vasc Boil, 2001, 21(12):1896-1901.

［8］ 刘晓方，吴辉. 他汀类药物在慢性心力衰竭防治中的作用［J］. 中国实用内科杂志, 2006, 26(17):1353-1354.

［9］ Afsarmanesh N, Horwich TB, Fonarow GC. Low serum total cholesterol is associated withincreased mortality in nonischemic heart failure［J］. J Am Coll Cardiol, 2006, 47(Suppl A):59A.

［10］Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-asso-ciated myopathy:a systematic review［J］. J Am coll cardiol, 2007, 49(23):2231-2237.

［11］Pliquett RU, Cornish KG, peuler JD, et al. Simvastatin normalize sau-tonomic neural control in experimental heart failure［J］.Circulation, 2003, 107（19）:2493.

［12］Thurmann PA, Kenedi P, Schidt A, et al. Influence of the angiotensinⅡantagonist valsartan on left vntricular hypertrophy in patients with essential hypertension［J］. Circulation, 1998, 98(19):2037-2042.

备注/Memo

备注/Memo:
收稿日期：2009-2-28.作者简介：黄善庆，主治医师Email:LcL0109@Yahoo.com.cn
更新日期/Last Update: 2010-01-05